Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Zacks research out dated July 1

<< Previous

Bullboard Posts

Next >>

Comment by baggerx99on Jul 02, 2021 3:14pm

228 Views

Post# 33485368

RE:Zacks research out dated July 1

Antibe is well on its way to getting the Phase 3 program for otenaproxesul underway with the initiation of the AME trial starting very soon. We don’t anticipate any issues with the company completing that trial in a timely manner and it should lead to the initiation of the Phase 3 adaptive trial in the first quarter of 2022. While partnering efforts are underway for the large global markets, it will likely be a while before the company is able to share any details as it is a notoriously long process. Upcoming milestones for the second half of 2021 include the data readout for the AME trial and the ‘End-of-Phase 2’ meeting with the FDA, with the timing of that meeting dictating how quickly the Phase 3 adaptive trial can get underway. After incorporating the financing in February 2021, the IP consolidation (which included issuing approximately 5.8 million shares to the owners of Antibe Holdings Inc.), and the change in the exchange rate our valuation has decreased to CAD$24.00 per share. However, there continues to exist a very large disconnect between our valuation and the share price, which investors could use to build or add to a position ahead of multiple catalysts by the end of 2021.